Pacific Biosciences Of California, Inc. (PACB)

$5.11

-0.02

(-0.39%)

Market is closed - opens 8 PM, 26 Feb 2024

Insights on Pacific Biosciences Of California, Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 27.35M → 55.69M (in $), with an average increase of 20.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -81.14M → -66.86M (in $), with an average increase of 10.3% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 42.5% return, outperforming this stock by 84.2%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 69.5% return, outperforming this stock by 155.2%

Performance

  • $5.04
    $5.32
    $5.11
    downward going graph

    1.47%

    Downside

    Day's Volatility :5.27%

    Upside

    3.86%

    downward going graph
  • $5.00
    $14.55
    $5.11
    downward going graph

    2.15%

    Downside

    52 Weeks Volatility :65.64%

    Upside

    64.88%

    downward going graph

Returns

PeriodPacific Biosciences Of California, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-40.23%
12.8%
0.0%
6 Months
-49.2%
11.6%
0.0%
1 Year
-41.73%
15.1%
-6.4%
3 Years
-85.71%
28.9%
-22.6%

Highlights

Market Capitalization
1.4B
Book Value
$2.63
Earnings Per Share (EPS)
-1.21
PEG Ratio
-0.17
Wall Street Target Price
11.42
Profit Margin
-152.97%
Operating Margin TTM
-142.14%
Return On Assets TTM
-10.92%
Return On Equity TTM
-48.53%
Revenue TTM
200.5M
Revenue Per Share TTM
0.79
Quarterly Revenue Growth YOY
113.3%
Gross Profit TTM
53.5M
EBITDA
-293.7M
Diluted Eps TTM
-1.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.01
EPS Estimate Next Year
-0.83
EPS Estimate Current Quarter
-0.32
EPS Estimate Next Quarter
-0.29

Analyst Recommendation

Buy
    73%Buy
    26%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Pacific Biosciences Of California, Inc.(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
12
12
Hold
5
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 123.48%

Current $5.11
Target $11.42

Company Financials

FY18Y/Y Change
Revenue
78.6M
↓ 15.88%
Net Income
-102.6M
↑ 11.25%
Net Profit Margin
-130.44%
↓ 31.81%
FY19Y/Y Change
Revenue
90.9M
↑ 15.6%
Net Income
-77.8M
↓ 24.12%
Net Profit Margin
-85.62%
↑ 44.82%
FY20Y/Y Change
Revenue
78.9M
↓ 13.2%
Net Income
29.4M
↓ 137.78%
Net Profit Margin
37.27%
↑ 122.89%
FY21Y/Y Change
Revenue
130.5M
↑ 65.43%
Net Income
-181.2M
↓ 716.34%
Net Profit Margin
-138.85%
↓ 176.12%
FY22Y/Y Change
Revenue
128.3M
↓ 1.69%
Net Income
-296.9M
↑ 63.85%
Net Profit Margin
-231.43%
↓ 92.58%
FY23Y/Y Change
Revenue
169.5M
↑ 32.12%
Net Income
-309.1M
↑ 4.1%
Net Profit Margin
-182.34%
↑ 49.09%
Q2 FY22Q/Q Change
Revenue
35.5M
↑ 6.92%
Net Income
-69.4M
↓ 17.81%
Net Profit Margin
-195.62%
↑ 58.84%
Q3 FY22Q/Q Change
Revenue
32.3M
↓ 8.9%
Net Income
-83.6M
↑ 20.5%
Net Profit Margin
-258.74%
↓ 63.12%
Q4 FY22Q/Q Change
Revenue
27.4M
↓ 15.34%
Net Income
-79.8M
↓ 4.5%
Net Profit Margin
-291.89%
↓ 33.15%
Q1 FY23Q/Q Change
Revenue
38.9M
↑ 42.21%
Net Income
-81.1M
↑ 1.64%
Net Profit Margin
-208.61%
↑ 83.28%
Q2 FY23Q/Q Change
Revenue
47.6M
↑ 22.3%
Net Income
-69.8M
↓ 13.94%
Net Profit Margin
-146.79%
↑ 61.82%
Q3 FY23Q/Q Change
Revenue
55.7M
↑ 17.06%
Net Income
-66.9M
↓ 4.24%
Net Profit Margin
-120.07%
↑ 26.72%
FY17Y/Y Change
Total Assets
144.1M
↑ 4.5%
Total Liabilities
58.0M
↑ 8.95%
FY18Y/Y Change
Total Assets
170.3M
↑ 18.18%
Total Liabilities
56.2M
↓ 3.05%
FY19Y/Y Change
Total Assets
148.0M
↓ 13.09%
Total Liabilities
93.1M
↑ 65.56%
FY20Y/Y Change
Total Assets
414.0M
↑ 179.74%
Total Liabilities
78.5M
↓ 15.66%
FY21Y/Y Change
Total Assets
2.0B
↑ 384.8%
Total Liabilities
1.2B
↑ 1449.24%
FY22Y/Y Change
Total Assets
1.8B
↓ 11.95%
Total Liabilities
1.2B
↓ 0.97%
Q2 FY22Q/Q Change
Total Assets
1.9B
↓ 3.13%
Total Liabilities
1.2B
↓ 0.65%
Q3 FY22Q/Q Change
Total Assets
1.8B
↓ 3.05%
Total Liabilities
1.2B
↓ 0.16%
Q4 FY22Q/Q Change
Total Assets
1.8B
↓ 2.85%
Total Liabilities
1.2B
↑ 0.99%
Q1 FY23Q/Q Change
Total Assets
1.9B
↑ 7.32%
Total Liabilities
1.2B
↑ 0.01%
Q2 FY23Q/Q Change
Total Assets
1.8B
↓ 2.57%
Total Liabilities
1.2B
↑ 0.11%
Q3 FY23Q/Q Change
Total Assets
1.9B
↑ 2.75%
Total Liabilities
1.1B
↓ 5.89%
FY18Y/Y Change
Operating Cash Flow
-66.4M
↓ 1.61%
Investing Cash Flow
-38.4M
↑ 2379.99%
Financing Cash Flow
107.2M
↑ 55.77%
FY19Y/Y Change
Operating Cash Flow
-78.3M
↑ 17.89%
Investing Cash Flow
62.0M
↓ 261.52%
Financing Cash Flow
26.5M
↓ 75.23%
FY20Y/Y Change
Operating Cash Flow
19.5M
↓ 124.9%
Investing Cash Flow
-219.3M
↓ 453.48%
Financing Cash Flow
251.8M
↑ 848.62%
FY21Y/Y Change
Operating Cash Flow
-111.2M
↓ 670.07%
Investing Cash Flow
-678.5M
↑ 209.38%
Financing Cash Flow
1.2B
↑ 364.42%
FY22Y/Y Change
Operating Cash Flow
-263.2M
↑ 136.74%
Investing Cash Flow
116.1M
↓ 117.11%
Financing Cash Flow
9.6M
↓ 99.18%
Q2 FY22Q/Q Change
Operating Cash Flow
-60.6M
↓ 23.37%
Investing Cash Flow
-60.3M
↓ 243.35%
Financing Cash Flow
455.0K
↓ 91.28%
Q3 FY22Q/Q Change
Operating Cash Flow
-63.1M
↑ 4.11%
Investing Cash Flow
53.9M
↓ 189.43%
Financing Cash Flow
3.1M
↑ 588.57%
Q4 FY22Q/Q Change
Operating Cash Flow
-60.6M
↓ 3.94%
Investing Cash Flow
80.4M
↑ 49.15%
Financing Cash Flow
819.0K
↓ 73.86%
Q1 FY23Q/Q Change
Operating Cash Flow
-94.7M
↑ 56.34%
Investing Cash Flow
-72.6M
↓ 190.24%
Financing Cash Flow
196.0M
↑ 23830.28%
Q2 FY23Q/Q Change
Operating Cash Flow
-41.7M
↓ 55.92%
Investing Cash Flow
-98.6M
↑ 35.89%
Financing Cash Flow
-4.7M
↓ 102.41%

Technicals Summary

Sell

Neutral

Buy

Pacific Biosciences Of California, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
-26.58%
-49.2%
-41.73%
-85.71%
-30.48%
Stryker Corporation
Stryker Corporation
15.36%
29.84%
35.35%
42.69%
89.37%
Boston Scientific Corp.
Boston Scientific Corp.
11.82%
32.86%
42.52%
69.49%
67.54%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
20.95%
16.97%
15.07%
3.9%
54.44%
Abbott Laboratories
Abbott Laboratories
7.85%
15.14%
18.91%
-2.39%
55.43%
Medtronic Plc
Medtronic Plc
1.12%
5.69%
2.61%
-27.85%
-7.1%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
NA
NA
-0.17
-1.01
-0.49
-0.11
NA
2.63
Stryker Corporation
Stryker Corporation
42.75
42.75
3.27
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
62.37
62.37
2.07
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.77
37.77
5.3
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
36.51
36.51
28.75
4.59
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
27.0
27.0
1.61
5.19
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Pacific Biosciences Of California, Inc.
Pacific Biosciences Of California, Inc.
Buy
$1.4B
-30.48%
NA
-152.97%
Stryker Corporation
Stryker Corporation
Buy
$134.3B
89.37%
42.75
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$97.9B
67.54%
62.37
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.7B
54.44%
37.77
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$206.5B
55.43%
36.51
14.27%
Medtronic Plc
Medtronic Plc
Buy
$113.1B
-7.1%
27.0
13.0%

Institutional Holdings

  • ARK Investment Management LLC

    11.15%
  • Vanguard Group Inc

    8.70%
  • BlackRock Inc

    8.48%
  • Madrone Advisors LLC

    6.14%
  • Sumitomo Mitsui Trust Holdings Inc

    5.03%
  • Nikko Asset Management Americas Inc

    5.03%

Corporate Announcements

  • Pacific Biosciences Of California, Inc. Earnings

    Pacific Biosciences Of California, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

pacbio develops comprehensive solutions for scientists that propel the field of genomics, improve science and research, and create positive impact globally. we provide sophisticated genomic analysis systems that deliver invaluable insights for scientists who strive to resolve complex genetic challenges. our strength comes from the dedication of our people, who are fueled by a desire to effect real, positive change. with a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

Organization
Pacific Biosciences Of California, Inc.
Employees
0
CEO
Mr. Christian O. Henry M.B.A.
Industry
Health Technology

FAQs